"Cramer Spotlights Arm Holdings as a Must-Own Stock"
Originally Published 2 years ago — by CNBC
In a recent segment, Jim Cramer provided his insights on various stocks. He suggested moving on from ImmunoGen as it's now part of AbbVie, staying with Realty Income for its stability, and being cautious with Micron, which could benefit from a PC refresh cycle. Cramer labeled Bitfarms as speculative and was not interested in Ramaco. He praised GE Healthcare for being undervalued and having great potential, found Coherent too expensive, and was very optimistic about Arm, recommending it as a stock to own due to its potential to dominate in multiple tech sectors. He was not supportive of Teva and did not understand how to value TKO.